Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma Clinical Trial

Official title:

A Phase 1 Study of Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00593008
• Other study ID #: 07-115
• Status: Terminated
• Phase: Phase 1
• First received: December 28, 2007
• Last updated: December 1, 2011
• Start date: October 2007
• Est. completion date: October 2009

Study information

• Verified date: December 2011
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.

Description:

• Because this is a study to determine the highest doses of temsirolimus and gemcitabine that can be given safely together, groups of 3 subjects will be treated at gradually increasing doses of the drugs. Each group of 3 subjects must complete 4 weeks of treatment (1 cycle) before the following group of 3 subjects can start treatment at the higher dose of drug.

• Temsirolimus will be given intravenously every week of the 28 day treatment cycle (days 1, 8, 15, 22). Gemcitabine will be given intravenously every other week of the treatment cycle (days 1. 15).

• During the study, participants will have weekly clinic visits where the following tests and procedures may be performed: Physical exam; vital signs; urine test; blood tests.

• A CT scan will be performed after every 2 cycles (8 weeks) to assess teh response of the tumor to the study treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: October 2009
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Previously untreated metastatic pancreatic adenocarcinoma, histologically proven.

• Measurable disease by RECIST criteria

• ECOG Performance Status 0 or 1

• Male or female, 18 years of age or older

• Life expectancy of >/= 12 weeks

• AST and ALT </= 2.5 x ULN

• Total bilirubin </= 1.5 x ULN

• Serum albumin >/= 2.5g/dL

• Absolute neutrophil count >/= 1500/mm3; platelets >/= 100,000/mm3; hemoglobin >/= 9.0 g/dL

• Serum creatinine </= 1.5 x ULN

• Subjects with diabetes must have adequate glycemic control, with fasting serum glucose </= 1.5 x ULN

• Female patients of childbearing age and male patients with partners of childbearing age must agree to use adequate birth control measures during the course of the study and for at least one month following withdrawal from the study

Exclusion Criteria:

• Previously treatment with gemcitabine or chemoradiation

• Diagnosis of a second malignancy within the last 3 years, except for adequately treated basal cell carcinoma or squamous cell skin cancer

• Ongoing cardiac dysrhythmias of NCI CTCAE grade >/= 2, atrial fibrillation, QTc prolongation to > 450 msec for males and >470 msec for females

• Known immunodeficiency disorders or active infections requiring treatment

• Pregnancy or breastfeeding

• Known brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease

• Prior radiation therapy or major surgery within 4 weeks of study entry

• Prior radiation therapy to > 25% of the bone marrow

• Subjects receiving other experimental or alternative therapies during the course of the trial will be excluded

• History of prior hypersensitivity to polysorbate

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Neoplasms

Intervention

Drug:
• Temsirolimus
Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
• Gemcitabine
Given intravenously every other week of each 28-day cycle.

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Brigham and Women's Hospital, Dana-Farber Cancer Institute, Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the dose-limiting toxicities and maximal tolerated doses of gemcitabine combined with temsirolimus		2 years	Yes
Primary	To determine whether order of administration of the drugs affects the above		2 years	No
Primary	To determine the dosing regimen appropriate for Phase 2 studies of the combination		2 years	No
Secondary	To document objective response rate and progression-free survival in patients treated with this combination		TBD	No